This Event Has Been Cancelled

Hanson Wade Group have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or disappointment this will cause. Please register your interest here if you would like updates on the meeting or topic.

Empower Oncology Model Selection, De-Risk Preclinical Asset Development

Selecting & Optimising Predictive & Cost-Effective Models to Enhance Target Selection, Facilitate Biomarker Discovery & Achieve Clinical Translatability

2026 is set to reshape the future of preclinical oncology.

As we close out 2025 with the UK accelerating its roadmap to phase out animal testing and SillaJen securing a landmark FDA approval using only organoid efficacy data, the momentum has never been stronger. With immunomodulating therapies surging and preclinical development costs continuing to climb, the pressure is on for biopharma to cut attrition and de-risk every preclinical decision.

The message is clear: investing in more trustworthy, physiologically relevant, and cost-effective models is now mission‑critical for successfully advancing assets worldwide.

Join your peers at the Tumour Models Summit Malmö as the industry's leading minds unite to navigate this paradigm shift and define the future of preclinical oncology.

The combination of relatively small size, yet high quality of the program was very enjoyable. Heavily focused on therapeutics. I learnt a lot.

Principal Scientist, Sprint Biosciences

 

Sprint Bioscience Logo

Chance to interact with Nordic-based research and CRO teams in the field of tumour models. Adequate time to meet with speakers and attendees. New results of research in immuno-oncology were presented.

Chief Scientific Officer, BlueWave Therapeutics

Blue Wave Therapeutics Logo

Interesting talks covering a broad variety of tumour models.

Senior Scientist, NEOGAP Therapeutics

Neogap Logo

Networking Image
Explore the Agenda

Hear the latest preclinical and translational data on tumour modelling, and gain first-hand insight into innovations on modelling for in vitro, in vivo, complex in vitro and more across multiple modalities.

Networking Image
Partner With Us

Position yourself as the partner of choice amongst leading model developers and solution providers to ensure your brand is at the heart of biopharma deals and collaborations.

Speaker Image
Join Nordic Oncology Industry Experts

Connect with preclinical, translational, discovery, pharmacology, and biology drug developers from the leading Nordic biopharma companies through focused presentations, panels, and networking designed to spark meaningful scientific and commercial conversations.